<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927992</url>
  </required_header>
  <id_info>
    <org_study_id>B1831011</org_study_id>
    <secondary_id>3082B1-4436</secondary_id>
    <nct_id>NCT00927992</nct_id>
  </id_info>
  <brief_title>Study Evaluating Liver Transplantation in Haemophilia Patients in Spain</brief_title>
  <official_title>Liver Transplantation in Haemophilia Patients in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will analyze survival and outcome of patients with severe haemophilia who undergo
      liver transplantation in Spain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probability Sample
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation</measure>
    <time_frame>Post liver transplantation up to Month 3</time_frame>
    <description>Cyclosporine, corticosteroids, tacrolimus, mycophenolate mofetil, everolimus were considered as immunosuppressive therapy after liver transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Acute Rejection of Liver Transplant</measure>
    <time_frame>Post liver transplantation up to Month 3</time_frame>
    <description>Any acute rejection of the liver transplant was clinically suspected and biopsy proven by central pathologist.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation</measure>
    <time_frame>Post liver transplantation up to Month 3</time_frame>
    <description>Number of participants who had liver transplantation after cirrhosis due to hepatitis C virus (HCV) infection and experienced recurrence of HCV infection post liver transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Survived After Liver Transplantation</measure>
    <time_frame>Post liver transplantation up to Month 3</time_frame>
    <description>Number of participants who survived after liver transplantation was reported. The death reported was a result of acute-related transplantation complications and end-stage liver disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Exogenous Clotting Factor Infusion During Liver Transplantation</measure>
    <time_frame>Up to Day 5 post liver transplantation</time_frame>
    <description>Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of Exogenous Clotting Factors Used During Liver Transplantation</measure>
    <time_frame>Up to Day 5 post liver transplantation</time_frame>
    <description>Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With and Without Hemophilia Requiring Immunosuppressive Therapy, Had Acute Rejection, Hepatitis C Viral Infection Recurrence and Who Survived After Liver Transplantation</measure>
    <time_frame>Post liver transplantation up to Month 3</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Hemophilia</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Patients with haemophilia who undergo liver transplantation</arm_group_label>
    <description>Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epidemiological Non interventional</intervention_name>
    <description>Epidemiological Non interventional</description>
    <arm_group_label>Patients with haemophilia who undergo liver transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with haemophilia who underwent liver transplantation and who have been followed-up
        at any site in Spain.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with haemophilia who underwent liver transplantation and who have been
             followed-up at any site in Spain.

        Exclusion Criteria:

          -  Patients without informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3082B1-4436&amp;StudyName=Study%20Evaluating%20Liver%20Transplantation%20in%20Haemophilia%20Patients%20in%20Spain%20%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>December 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2013</results_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hemophiliac Participants With Liver Transplant</title>
          <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hemophiliac Participants With Liver Transplant</title>
          <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.45" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Type A and B Hemophilia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation</title>
        <description>Cyclosporine, corticosteroids, tacrolimus, mycophenolate mofetil, everolimus were considered as immunosuppressive therapy after liver transplantation.</description>
        <time_frame>Post liver transplantation up to Month 3</time_frame>
        <population>Evaluable population included all the participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation</title>
          <description>Cyclosporine, corticosteroids, tacrolimus, mycophenolate mofetil, everolimus were considered as immunosuppressive therapy after liver transplantation.</description>
          <population>Evaluable population included all the participants who met the eligibility criteria.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cyclosporine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tacrolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycophenolate Mofetil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Everolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Rejection of Liver Transplant</title>
        <description>Any acute rejection of the liver transplant was clinically suspected and biopsy proven by central pathologist.</description>
        <time_frame>Post liver transplantation up to Month 3</time_frame>
        <population>Evaluable population included all the participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Rejection of Liver Transplant</title>
          <description>Any acute rejection of the liver transplant was clinically suspected and biopsy proven by central pathologist.</description>
          <population>Evaluable population included all the participants who met the eligibility criteria.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation</title>
        <description>Number of participants who had liver transplantation after cirrhosis due to hepatitis C virus (HCV) infection and experienced recurrence of HCV infection post liver transplantation.</description>
        <time_frame>Post liver transplantation up to Month 3</time_frame>
        <population>Evaluable population included all the participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation</title>
          <description>Number of participants who had liver transplantation after cirrhosis due to hepatitis C virus (HCV) infection and experienced recurrence of HCV infection post liver transplantation.</description>
          <population>Evaluable population included all the participants who met the eligibility criteria.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Survived After Liver Transplantation</title>
        <description>Number of participants who survived after liver transplantation was reported. The death reported was a result of acute-related transplantation complications and end-stage liver disease.</description>
        <time_frame>Post liver transplantation up to Month 3</time_frame>
        <population>Evaluable population included all the participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived After Liver Transplantation</title>
          <description>Number of participants who survived after liver transplantation was reported. The death reported was a result of acute-related transplantation complications and end-stage liver disease.</description>
          <population>Evaluable population included all the participants who met the eligibility criteria.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Exogenous Clotting Factor Infusion During Liver Transplantation</title>
        <description>Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.</description>
        <time_frame>Up to Day 5 post liver transplantation</time_frame>
        <population>Evaluable population included all the participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Exogenous Clotting Factor Infusion During Liver Transplantation</title>
          <description>Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.</description>
          <population>Evaluable population included all the participants who met the eligibility criteria.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bolus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Continuous infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose of Exogenous Clotting Factors Used During Liver Transplantation</title>
        <description>Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.</description>
        <time_frame>Up to Day 5 post liver transplantation</time_frame>
        <population>Evaluable population included all the participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Exogenous Clotting Factors Used During Liver Transplantation</title>
          <description>Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.</description>
          <population>Evaluable population included all the participants who met the eligibility criteria.</population>
          <units>International Unit/kilogram (IU/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.88" spread="30.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With and Without Hemophilia Requiring Immunosuppressive Therapy, Had Acute Rejection, Hepatitis C Viral Infection Recurrence and Who Survived After Liver Transplantation</title>
        <time_frame>Post liver transplantation up to Month 3</time_frame>
        <population>Data was not analyzed as only hemophiliac participants were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Hemophiliac Participants With Liver Transplant</title>
            <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Hemophilia Requiring Immunosuppressive Therapy, Had Acute Rejection, Hepatitis C Viral Infection Recurrence and Who Survived After Liver Transplantation</title>
          <population>Data was not analyzed as only hemophiliac participants were enrolled in the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There were no adverse events collected in this retrospective study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hemophiliac Participants With Liver Transplant</title>
          <description>Participants with hemophilia (type A or B) who had undergone a liver transplant were observed for 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No outcomes were specified in the study protocol. Designation of outcomes as primary and secondary was based on study team’s input as study neither specifies nor prioritizes the outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

